Bundibugyo virus, a species within the Ebolavirus genus, has historically carried case fatality rates exceeding 30%, and until now no targeted therapeutic had demonstrated clear clinical success against it in a documented human case. A single survivor who received experimental combination therapy challenges the assumption that approved Ebola treatments translate poorly across viral species — and signals a potentially broader antiviral toolkit for filovirus outbreaks.
The case centers on an individual infected with Bundibugyo virus who was treated under emergency use authorization with MBP134, a bispecific monoclonal antibody cocktail, in combination with remdesivir and intensive supportive care. The patient recovered fully and was discharged 22 days after symptom onset. MBP134 targets two distinct epitopes on the Ebolavirus glycoprotein and was originally developed to broaden coverage across multiple filovirus species, making Bundibugyo a scientifically rational but previously untested application. Remdesivir, a nucleoside analog that inhibits viral RNA polymerase, added a mechanistically distinct antiviral layer to the regimen.
This report is significant not because it establishes efficacy — a single case can never do that — but because it establishes biological plausibility and clinical safety for a combination that had no human-use record in this specific pathogen. In the broader filovirus research landscape, the success of monoclonal antibodies like mAb114 and REGN-EB3 against Zaire ebolavirus during the 2018–2020 Democratic Republic of Congo outbreak set a high bar. Whether cross-reactive antibodies like MBP134 can replicate that performance across less-studied Ebolavirus species is an open and urgent question. This case will almost certainly support compassionate use protocols and accelerate formal clinical evaluation. The core limitation is obvious: n=1 prevents any statistical inference, and spontaneous recovery from Bundibugyo infection, while rare, cannot be excluded. Still, for clinicians facing future outbreaks of this neglected filovirus, this case provides the first documented therapeutic roadmap.